Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1988-02-03
1989-09-19
Robinson, Douglas W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514300, 514303, 514313, 514386, A61K 3150, A61K 31495, A61K 3144, A61K 3147, A61K 31415
Patent
active
048681822
ABSTRACT:
This invention relates to the synergistic enhancement of certain antihypertensives by the conjunctive use of certain cardiotonic agents. More specifically, this invention relates to the enhancement of the blood pressure lowering effect achieved with alpha.sub.1 -adrenoceptor antagonists by the conjunctive administration of cardiotonic agents possessing the ability to specifically inhibit cyclic AMP-phosphodiesterase.
REFERENCES:
patent: 4130647 (1978-12-01), Taylor
patent: 4578389 (1986-03-01), Schickaender et al.
patent: 4584299 (1986-04-01), Steffen et al.
patent: 4601897 (1986-07-01), Saxton
patent: 4623651 (1986-11-01), Grisar et al.
patent: 4670450 (1987-06-01), Schenttler et al.
J. Pharm. Pharmacol. 1980, 32(1) pp. 74-76-Dadkar et al.
European J. Pharmacology 65 (1980) 243-247-D'Armiento et al.
Handbook of Hypertension, vol. 3-Pharm. of Antihypertensive Drugs: 1984 pp. 239-248.
Henley III Raymond J.
Merrell Dow Pharmaceuticals Inc.
Nesbitt Stephen L.
Robinson Douglas W.
Sayles Michael J.
LandOfFree
Enhancement of prazosin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enhancement of prazosin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhancement of prazosin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-368874